



S2 Fig. Survival outcomes in the subgroup of patients who received both regimens as second-line treatment and above. (A) Overall survival. (B) Progression-free survival_{C+E}. (C) Progression-free survival_C. (D) Progression-free survival_E. (E) Progression-free survival₁. (F) Progression-free survival₂. C, cyclin-dependent kinase 4/6 inhibitor; E, everolimus; NE, not estimated.